Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial-Reference-Cited by-同舟云学术

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

Published:2015-05-26 Issue:5 Volume:10 Page:e0125350
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Anota Amélie,Mouillet Guillaume,Trouilloud Isabelle,Dupont-Gossart Anne-Claire,Artru Pascal,Lecomte Thierry,Zaanan Aziz,Gauthier Mélanie,Fein Francine,Dubreuil Olivier,Paget-Bailly Sophie,Taieb Julien,Bonnetain Franck

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM);I Trouilloud;Eur J Cancer,2014

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;T Conroy;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;DD Von Hoff;N Eng J Med,2013

4. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up;T Seufferlein;Ann Oncol,2012

5. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial;S Gourgou-Bourgade;J Clin Oncol,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in sonodynamic therapy strategies for pancreatic cancer;WIREs Nanomedicine and Nanobiotechnology;2024-01

3. How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales;Quality of Life Research;2022-07-09

4. Patient Reported Outcomes and Quality of Life;Pancreatic Cancer: A Multidisciplinary Approach;2022

5. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX);European Journal of Cancer;2020-09